Posted on Monday 21st of September 2015
Ellie Williams has won the poster prize for the Biochemical Society's 78th Harden Conference: Protein Kinases in Health and Disease. She presented the recent work she and her colleagues have done investigating a pre-clinical compound (K04284) that may have applications in the rare disease Fibrodisplasia Ossificans Progressiva (FOP). FOP is caused by a single point mutation in the ALK2 kinase leading to uncontrolled bone formation and there is currently no treatment. K04284 is already in Phase 2 clinical trials for the treatment of some cancers and its additional activity against ALK2 provides exciting potential for fast track clinical trials for FOP.
Posted on Thursday 3rd of September 2015
Through a novel open source approach the molecule has been made freely available to the cancer research community to help discover new therapeutic strategies for cancer patients sooner.
Posted on Thursday 27th of August 2015
Posted on Friday 17th of July 2015
Professors Markus Perkmann from Imperial College London and Henri Schildt of Aalto University School of Business report on their findings in the journal Research Policy on managing open data partnerships and the role of boundary organizations such as the SGC.
Open data partnerships between firms and universities: The role of boundary organizations
Markus Perkmanna & Henri SchildtResearch Policy Volume 44, Issue 5, June 2015, Pages 1133–1143
Posted on Thursday 16th of July 2015
WD Repeat domain 5 (WDR5) is a critical part of the human trithorax/COMPASS complexes which are responsible for methylation of lysine 4 on histone 3 (H3K4) via one of several catalytic subunits, Mixed-Lineage Leukemia (MLL), MLL2, MLL3, or MLL4 proteins. Early hypotheses that antagonism of the MLL-WDR5 interaction might lead to reduction of H3K4 methylation encouraged us to search for small-molecule inhibitors of this interaction (PubMed 22989411). More recently, through a collaboration with the Ontario Institute for Cancer Research (OICR) we developed the chemical probe, OICR-9429, a potent, selective, and cell-penetrant WDR5 antagonist. Treatment of normal cells with OICR-9429 indicates... more
Posted on Friday 10th of July 2015
Bromo and extra-terminal (BET) proteins tether the transcriptional machinery to chromatin, stimulating programmes that are often hijacked in disease.
Posted on Thursday 18th of June 2015
Posted on Friday 12th of June 2015
In their most recent issue of Show me the Evidence, the Canadian Institutes for Health Research (CIHR) included a feature piece on SGG's research in an interview with SGC-Toronto's Chief Scientist, Dr Cheryl Arrowsmith.
Posted on Monday 25th of May 2015
Pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) join forces with small and medium-sized enterprise (SMEs) as well as universities and hospitals in an Innovative Medicines Initiative (IMI) supported public private partnership, ULTRA-DD. In this project, we aim to define and validate new drug targets in inflammatory and auto-immune diseases by testing high quality chemical probes and antibodies in patient-cell derived assays to facilitate a greater understanding of disease pathology.